Cannabis Bioscience International Holdings, Inc. (CBIH) Cost of Revenue (2022 - 2026)

Cannabis Bioscience International Holdings has reported Cost of Revenue for 5 years, with the latest figure at $3045.0 in Q1 2026.

• Quarterly Cost of Revenue fell 84.3% year-over-year to $3045.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $26233.0 (down 42.27% YoY) and the FY2025 annual result came in at $40106.0, down 12.05% from the prior year.
• Cost of Revenue declined to $3045.0 in Q1 2026 per CBIH's latest filing, from $10500.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $24120.0 in Q1 2023 and troughed at $3045.0 in Q1 2026.
• A 5-year average of $11043.6 and a median of $9349.0 in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue soared 112.86% in 2023, then sank 84.3% in 2026.
• Over 5 years, Cost of Revenue stood at $7090.0 in 2022, then jumped by 112.86% to $15092.0 in 2023, then tumbled by 48.3% to $7803.0 in 2024, then surged by 34.56% to $10500.0 in 2025, then tumbled by 71.0% to $3045.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3045.0, $10500.0, and $8143.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.